CAMBRIDGE, UK, Feb. 17 /PRNewswire/ -- Purely Proteins Ltd (Cambridge, UK) and Abcam Ltd (Headquarters, Cambridge, UK) today announced a set of collaborative programs leading to the development of protein-antibody pairs that have relevance in pharmaceutical development and span the entire human proteome.
The two companies have formed a collaboration that covers the focused production of families of therapeutically relevant proteins and protein domains together with their corresponding antibodies.
Purely Proteins' TargetBASE database product is being used to provide detailed information about known members of specific therapeutically relevant protein families. TargetBASE's ability to define relationships between the proteins within a family enables their detailed exploration as targets for pharmaceutical and biotherapeutic development. Highly specific antibodies to these therapeutically relevant targets will be designed and produced using Abcam's proprietary processes.
The fruits of this collaboration are being marketed by both companies and will commence with the immediate launch of a number of Protein Tyrosine Phosphatase proteins (PTPs) as off-the-shelf products. The PTPs are validated targets for drug discovery. PTP-1B, a key member of the family, is a proven therapeutic target in diabetes and obesity.
Other protein/antibody combinations that are of specific interest to clients can be accessed immediately via fee-for-service arrangements with the two companies.
Commenting on the collaboration, Abcam's Chief Executive Officer, Dr Jonathan Milner, said, "This collaboration will accelerate our continuing efforts to provide a comprehensive range of antibody-related products for use in drug discovery research and development. We are delighted to be working with Purely Proteins, a company with extensive experience in cloning, protein expression and purification, to provide full-length proteins and active protein domains for use in pharmaceutical development. This, combined with Purely Proteins' use of TargetBASE to define protein relationships, will enable us to add further important products to our expanding portfolio very rapidly."
Dr David Bailey, Chief Executive Officer of Purely Proteins, said, "Abcam is an ideal partner for Purely Proteins in this area. They have considerable expertise in the sourcing, production and sale of antibodies and related products, and have an active program of expansion and development of their antibody range. We are continuing to expand our protein product lines, and access to Abcam's sales and marketing channels will enable Purely Proteins to reach new pharma and biotech clients quickly and efficiently."
The full Abcam product range can be viewed at http://www.abcam.com/. Details of Purely Proteins' products can be obtained from http://www.purelyproteins.com/.
Abcam is committed to developing its product range to bring their customers fast access to reliable products, great customer service and thousands of the best antibodies and reagents for research purposes. To keep up with the rapid pace of scientific research Abcam develops over 500 new products per month. The Abcam online catalog is updated daily to enable researchers around the world to find the antibodies and information they need in seconds.
Purely Proteins uses its proprietary affinity purification technologies and computational software for information integration to exploit novel relationships between discovery targets and their corresponding chemical ligands. Purely Proteins' databases house both public domain and proprietary information of direct relevance to drug discovery, linking proteomics to established discovery disciplines such as structural biology and medicinal chemistry.
Dr David Bailey
Chief Executive Officer
254 Cambridge Science Park
Tel: +44 1223 426400
Fax: +44 1223 426003
Mr Mark Long
21 Cambridge Science Park
Tel: +44 1223 472030
Fax: +44 1223 472038
Purely Proteins Ltd